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Available online 20 August 2016Background:Wehave developed a recombinant B cell epitope-based vaccine (BM32) for allergen-speciﬁc immu-
notherapy (AIT) of grass pollen allergy. The vaccine contains recombinant fusion proteins consisting of allergen-
derived peptides and the hepatitis B surface protein domain preS as immunological carrier.
Methods:We conducted a randomized, double-blind, placebo-controlled AIT study to determine safety, clinical
efﬁcacy and immunologicalmechanismof three subcutaneous injections of three BM32doses adsorbed to alumi-
numhydroxide versus aluminumhydroxide (placebo) appliedmonthly to grass pollen allergic patients (n=70).
Primary efﬁcacy endpoint was the difference in total nasal symptom score (TNSS) through grass pollen chamber
exposure before treatment and 4 weeks after the last injection. Secondary clinical endpoints were total ocular
symptom score (TOSS) and allergen-speciﬁc skin response evaluated by titrated skin prick testing (SPT) at the
same time points. Treatment-related side effects were evaluated as safety endpoints. Changes in allergen-
speciﬁc antibody, cellular and cytokine responses were measured in patients before and after treatment.
Results: Sixty-eight patients completed the trial. TNSS signiﬁcantly decreased with mean changes of −1.41
(BM32/20 μg) (P = 0.03) and −1.34 (BM32/40 μg) (P = 0.003) whereas mean changes in the BM32/10 μg
and placebo groupwere not signiﬁcant. TOSS and SPT reactions showed a dose-dependent decrease. No systemic
immediate type side effects were observed. Only few grade 1 systemic late phase reactions occurred in BM32
treated patients. The number of local injection site reactionswas similar in actively and placebo-treated patients.
BM32 induced highly signiﬁcant allergen-speciﬁc IgG responses (P b 0.0001) but no allergen-speciﬁc IgE.
Allergen-induced basophil activation was reduced in BM32 treated patients and addition of therapy-induced
IgG signiﬁcantly suppressed T cell activation (P = 0.0063).
Conclusion: The B cell epitope-based recombinant grass pollen allergy vaccine BM32 is well tolerated and few
doses are sufﬁcient to suppress immediate allergic reactions as well as allergen-speciﬁc T cell responses via a se-
lective induction of allergen-speciﬁc IgG antibodies. (ClinicalTrials.gov number, NCT01445002.)
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Key words:
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Immunotherapy1. Introduction
Allergen-speciﬁc immunotherapy (AIT) is the only disease-
modifying treatment for allergywhich prevents the progression of aller-
gic rhinitis towards asthma (Larché et al., 2006, Jacobsen et al., 2007).
Clinical and immunological effects of AIT are long-lasting, even after dis-
continuation (Durham et al., 1999). Furthermore, AIT has a cost-savingValenta).
. This is an open access article undereffect when compared to symptomatic drug treatment (Hankin and
Cox, 2014). However, several factors limit the broad application of AIT.
Current allergy vaccines are based on natural allergen extracts which
are often of poor quality (e.g., varying allergen compositions, lack of im-
portant allergens, contaminations) and may induce severe immediate
and late phase side effects (Focke et al., 2008, Casset et al., 2012,
Winther et al., 2006, Focke et al., 2010). Accordingly current treatment
schedules require inconvenient, multiple administrations of gradually
increasing doses and, in sensitive patients, the therapeutically effective
maintenance dose often cannot be reached due to side effects. As a re-
sult, the real-life adherence to AIT is low (Kiel et al., 2013).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patients characteristics at baseline
Characteristic Placebo
N = 18
S1, 10 μg
N = 17
S2, 20 μg
N = 18
S3, 40 μg
N = 17
Age
Mean 29.4 28.9 28.6 29.8
SD 8.0 7.7 5.2 7.7
Range 21–52 19–48 23–47 19–52
Gender
Male (%) 7 (39%) 8 (47%) 9 (50%) 10 (59%)
Height (cm)
Mean 172.6 173.1 173.7 175.6
SD 9.0 8.4 9.4 9.2
Range 157–197 158–190 163–194 161–189
Weight (kg)
Mean 69.4 69.1 72.0 74.4
SD 15.8 12.2 14.1 12.4
Range 51–114 52–90 53–98 58–98
BMI (kg/m2)
Mean 23.0 22.9 23.8 24.1
SD 3.2 3.0 3.8 3.0
Range 18.4–29.4 19.0–28.0 18.7–33.3 19.5–30.1
TNSS (baseline)
Mean 8.4 8.7 8.2 8.1
SD 0.2 0.4 0.2 0.3
Range 6.0–12.0 5.9–12.0 4.9–10.1 4.6–11.2
Total IgE (kU/l)
Mean 156.4 268.8 437.6 260.2
SD 101,5 264,1 343,5 121,2
Range 20.9–485.0 26.3–921.0 30.4–1026.0 25.4–1442.0
sIgE timothy grass (kU/l)
Mean 22.5 32.4 39.8 31.3
SD 25,4 27,3 39,3 24,2
Range 2.3–100.0 3.3–100.0 1.6–100.0 1.7–100.0
Phl p 7 positive
N 0 5 2 1
SPT grass pollen (mm2)
Mean 68.1 72.8 59.5 71.7
SD 33.9 37.8 31.3 45.8
Range 9.6–140.6 26.3–136.7 11.7–135.7 14.7–172.3
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disease-causing allergens has now opened the door for new forms of
allergen-speciﬁc immunotherapy which allow reduced side effects
and targeting of speciﬁc pathways of the allergic immune response
(Niederberger et al., 2004, Creticos et al., 2006, Valenta et al., 2010).
We have developed a strategy for AIT (i.e., B cell epitope-based allergy
vaccines) which is based on fusion proteins consisting of non-
allergenic peptides which are derived from the IgE binding sites of
disease-causing allergens but do not bind IgE themselves and PreS, a
surface protein from hepatitis B which serves as a non-allergenic carrier
protein providing T cell help (Focke-Tejkl et al., 2015). The allergen-
derived peptides used for the construction of the B cell epitope-based
allergy vaccines lack IgE reactivity and therefore do not induce IgE-
mediated side effects but focus blocking allergen-speciﬁc IgG towards
the IgE binding sites of the allergen. In the vaccine allergen-speciﬁc T
cell epitopes are reduced as much as possible (Focke-Tejkl et al., 2015;
Niederberger et al., 2015) because, when present in previously
engineered hypoallergenic allergen derivatives, they were found to
cause late phase side effects (Campana et al., 2015). In the B cell
epitope-based allergy vaccine concept the T cell help for the induction
of allergen-speciﬁc IgG antibodies comes from T cell epitopes of the
non-allergenic PreS carrier protein (Focke-Tejkl et al., 2015).
Since grass pollen is one of the most important allergen sources
world-wide and causes severe respiratory manifestations in allergic
patients (Suphioglu et al., 1992), we constructed a grass pollen vac-
cine consisting of four recombinant derivatives of the four major
timothy grass pollen allergens (i.e., Phl p 1, Phl p 2, Phl p 5, Phl p
6) based on the B cell epitope-based strategy. It has been demon-
strated that with a combination of these four timothy grass pollen al-
lergens all grass pollen allergic patients can be diagnosed (Linhart
et al., 2005, Hatzler et al., 2012). The hypoallergenic peptides incor-
porated in the grass pollen allergy vaccine have been identiﬁed in
combined approaches using epitope mapping and structural analy-
ses of the allergens (Focke et al., 2001, Focke-Tejkl et al., 2014,
Focke-Tejkl et al., 2015). The in vitro immunological characteriza-
tion, experimental animal data and a safety skin test study per-
formed in grass pollen allergic patients indicated that the vaccine
lacks allergenic activity and has the potential to induce allergen-
speciﬁc IgG antibodies upon vaccination, which compete with aller-
gic patients IgE antibodies for the binding sites on the natural aller-
gens (Focke-Tejkl et al., 2015, Niederberger et al., 2015).
The current double-blind, placebo-controlled study was designed as
a safety and dose-ﬁnding study carried out in the Vienna Challenge
Chamber (VCC) to investigate the underlying immunological mecha-
nisms and potential clinical effects of the B cell epitope-based grass pol-
len allergy vaccine in allergic patients for the ﬁrst time.
2. Methods
2.1. Patients, inclusion and exclusion criteria, randomization
Adult male and female patients (18–60 years) suffering from grass
pollen-induced allergic rhinoconjunctivitis for at least two years were
recruited. Grass pollen-speciﬁc sensitization was conﬁrmed by positive
skin prick test to timothy grass pollen extract as well as by the presence
in serum of grass pollen-speciﬁc IgE antibodies (at least 0.7kUA/l) as
demonstrated by ImmunoCAP (Thermoﬁsher, Uppsala, Sweden).
Grass pollen-speciﬁc clinical reactivity with at least moderate symp-
toms of allergic rhinitis (itching, sneezing, rhinorrhea, nasal obstruc-
tion) documented by a TNSS of at least 6 within the ﬁrst two hours of
a 6 hour screening challenge in the Vienna Challenge Chamber (VCC)
were required.
Patients with unstable asthma and other intercurrent diseases
like perennial allergies or structural nasal abnormalities were not el-
igible. A detailed list of inclusion and exclusion criteria can be found
in the study protocol (supplementary data). Excludedwere pregnantwomen, subjects who received grass pollen speciﬁc AIT within 2
years prior to study start and patients under prohibited medications
(i.e., depot corticosteroids for 12 weeks, oral corticosteroids for
8 weeks and inhaled corticosteroids for 4 weeks prior to study start
and during entire study).
Block randomization with stratiﬁcation for disease severity (moder-
ate or severe) was conducted to ensure that patients in the four treat-
ment arms had comparable disease severity as assessed by TNSS and
titrated skin prick test during screening allergen challenge. The
randomisation lists were generated by a CRO using a block size of 4
(Software RUNCODE Version 3.6, idv Gauting). Paper listings were
used for performing the randomization and number allocation. Only
the data manager generating the randomisation list at the CRO was un-
blinded. All other personnel at the CRO conducting data management
and statistical analysis were blinded. Likewise, all personnel at the
study site, in the laboratories performing analyses and at the sponsor
were blinded.
One subject was excluded due to abnormal laboratory values before
treatment. At the time of randomization there were no relevant differ-
ences between the subjects allocated to the four treatment groups re-
garding demographic data, TNSS in response to grass pollen exposure
in the challenge chamber and grass pollen-speciﬁc immediate type
skin responses (Table 1). Patients showed IgE reactivity to the recombi-
nant timothy grass pollen allergens (Phl p 1, Phl p 2, Phl p 5, Phl p 6) but
lacked relevant IgE reactivity to BM321, BM322, BM325 and BM326
(Supplemental Fig. 1). Patients with IgE reactivity against a clinically
relevant minor allergen (i.e., Phl p 7) which was not included in BM32
were unevenly distributed in the four treatment groups (Table 1).
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Sample size estimation for comparison of 3 treatments with a con-
trol was done according to (Horn and Vollandt, 1998). The difference
between placebo and the highest dose group in the change of the
TNSS score before and after treatment was assumed to be 2.65 (stan-
dard deviation 2.0). A sample size of 13 patients was derived, which ﬁ-
nally led to a size of 15patients per groupwith respect to a 15%drop-out
rate (one-sided signiﬁcance level 5%, power 90%).
2.3. Study design, study drug and concomitant medication
This study was a safety and dose ﬁnding phase II study investigating
safety and dose-dependent effects of three subcutaneous injections of
three different doses of an aluminumhydroxide-adsorbed, recombinant
grass pollen vaccine (BM32) versus placebo (i.e., aluminum hydroxide
alone). The grass pollen allergy vaccine BM32 included four recombi-
nant fusion proteins consisting of non-allergenic peptides derived
from the IgE-binding sites of the major grass pollen allergens (Phl p 1,
Phl p 2, Phl p 5, Phl p 6) fused to hepatitis B virus-derived PreS which
were adsorbed to aluminum hydroxide (Biomay AG, Polymun Scientiﬁc
GmbH Vienna) (Fig. 1) (Focke-Tejkl et al., 2015). BM32/S1 contained
10 μg, BM32/S2 20 μg and BM32/S3 40μg of each of the four fusion pro-
teins. Ready to use suspensions of BM32 of each of the three doses (S1,
S2, S3) and placebo (aluminum hydroxide) were provided in single use
2ml glass vials. Four hundred μl were applied per s.c. injection. On de-
mand use of inhaled short acting beta-agonists, antihistamines and de-
congestants with discontinuation at least 24 hours prior to next
evaluationwas allowed. Any concurrentmedication had to be approved
by the investigator and was recorded.
The effects of vaccination on responses to grass pollen allergen chal-
lenge in the Vienna challenge chamber (VCC) and by skin testing were
tested. In addition, effects of vaccination on grass pollen-speciﬁc hu-
moral and cellular immune responses were studied in detail. TheFig. 1.Characterization of the recombinant fusion proteins in BM32. Shown are the three-dimen
6 (accession numbers for sequences in brackets) with the peptides (position, amino acid seq
BM322, BM325, BM326study has been registered at https://clinicaltrials.gov under the identiﬁ-
er: NCT01445002. It was conducted outside the grass pollen season be-
tween October 2011 (screening) and April 2012 (data base lock). The
trial was approved by the Clinical Pharmacology Ethics Committee,
Vienna, Austria and by the Austrian Regulatory Agency (AGES).Written
informed consent was obtained from each patient ahead of any study
speciﬁc procedure, and the study was conducted according to the prin-
ciples of the declaration of Helsinki and the International Conference on
Harmonization of Good Clinical Practice guidelines.
Seventy eight subjects were screened and 71 were randomized to
the four treatment groups (S1, S2, S3, Placebo) (Fig. 2A) (Table 1). One
to 4 weeks after skin testing and after the baseline session in the chal-
lenge chamber subjects received the ﬁrst injection followed by two ad-
ditional injections with approximately 1 month intervals (Fig. 2B). At
these visits safety assessments including urine pregnancy testing in
womenwere performed. During the entire study period, patients docu-
mented adverse events and concomitantmedication in a personal diary.
Approximately 4 weeks after the last injection subjects underwent skin
testing and a second session in the challenge chamber. Blood samples
for immunological analysis were obtained during screening and during
the second challenge session. A followup visit wasdone 1–2weeks later
(Fig. 2B).2.4. Clinical endpoints and assessments
Primary efﬁcacy endpoint was the difference in TNSS (itching,
sneezing, rhinorrhea, nasal obstruction) before and after treatment.
Clinical secondary endpoints were the change of TOSS (ocular itch, tear-
ing, conjunctival injection) and changes in grass pollen-speciﬁc titrated
skin prick test reactivity before and after treatment in terms of sum of
wheal areas and threshold concentrations. Primary safety endpoint
was the frequency and severity of treatment-related local and systemic
adverse reactions.sional structures of the four timothy grass pollen allergens Phl p 1, Phl p 2, Phl p 5 and Phl p
uences) indicated in red which are part of the recombinant PreS fusion proteins BM321,
78 subjects were screened
71 subjects were randomised
70 subjects were treated
1 subject was excluded due to abnormal laboratory values 
(Exclusion Criterion No. 6)
7 subjects were excluded
2 withdrew consent
2 were not clinically reactive (Inclusion Criterion No. 4) 
1 had negative sIgE (CAP) to timothy grass pollen
(Inclusion Criterion No. 6)
1 had acute respiratory disease (Exclusion Criterion No. 3)
1 had autoimmune disease (Exclusion Criterion No. 6)
1 subject withdrew consent
18 subjects completed
the trial per protocol
Placebo; N = 18
1 subject withdrew consent
18 subjects completed
the trial per protocol
16 subjects completed
the trial per protocol 
16 subjects completed
the trial per protocol
A
B
Fig. 2. Study enrolment, randomization (A) and study design (B). Patients screening, baseline SPT, blood sampling and baseline challenge chamber session (VCC) occurred in a period of
28 day before treatment was started. Then patients were randomized and received three subcutaneous injections in 3–4 week intervals. Three–4 weeks after the last injection SPT was
performed, a blood sample was taken and patients underwent the second challenge chamber session (VCC). The concluding follow up visits were scheduled approximately 2 weeks
after the last challenge chamber session.
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conducted in the Vienna Challenge Chamber (VCC) before and approx-
imately 4 weeks after treatment (Horak et al., 2009). During the 6 hour
challenge, the chamber was charged with fresh air, which was cleaned,
cooled, dried and then loadedwith a qualitatively and quantitatively de-
termined load of mixed grass pollen from Dactylis glomerata, Lolium
perenne, Phleum pratense and Anthoxanthum odoratum. According to
continuous monitoring patients were exposed to constant humidity
(approximately 40%), temperature (approximately 24°C) and allergen
loads (approximately 1500 pollen grains per cubic meter) throughout
the exposure period. Patients (up to 20 per session) were under con-
stant supervision by medical staff outside the chamber.TNSS comprised the four components of nasal itching, sneezing,
rhinorrhea and nasal congestion. Each symptom was scored on a four
point scale from 0 to 3 (0= absence of symptoms— 3 = severe symp-
toms) (Pfaar et al., 2014) giving a TNSS range from 0 to 12. Patients
completed the TNSS assessment on a touch screenmonitor immediately
prior to entering the chamber, and at 15minute intervals during the 6 h
allergen challenge. TOSS was evaluated accordingly. Furthermore nasal
air ﬂow was measured using active anterior rhinomanometry immedi-
ately prior to entering the chamber and at 30 minute intervals during
the challenge.
A titrated skin prick test was performed in duplicates before and
4weeks after treatment. A registered standardized timothy grass pollen
47P. Zieglmayer et al. / EBioMedicine 11 (2016) 43–57extract (Stallergenes, Antony, France) was diluted in 1:2 steps with a
maximal dilution of 1:128 and the threshold concentration necessary
to elicit a positive skin reaction was determined (Drachenberg et al.,
2001).
Recordings of concomitant medication and adverse events (local
and systemic reactions) were evaluated by keeping daily diaries.
Treatment-related adverse events were recorded in the CRF and graded
according to “Allergen immunotherapy — a position paper of the Ger-
man Society for Allergology and Clinical Immunology” (Kleine-Tebbe
et al., 2001). Patients were monitored in the study center for at least
30 minutes after injection of the investigational product.
2.5. Immunological analyses
Immunological endpoints were changes in allergen-speciﬁc IgG, IgG
subclass (IgG1-IgG4) and IgE levels, in vitro allergen-induced cytokine
responses and allergen-speciﬁc basophil activation as measured by
CD203c expression before and four weeks after end of treatment.
Allergen-induced T cell proliferation was assessed after end of treat-
mentwith allergens in the presence of pre- and post-treatment sera. Re-
combinant grass pollen allergens (rPhl p 1, rPhl p 2, rPhl p 5 and rPhl p
6) and recombinant BM32 proteins (BM321, BM322, BM325 and
BM326) used in the immunological assays were produced by Biomay
AG (Vienna, Austria). Recombinant PreS was expressed and puriﬁed as
described (Niespodziana et al., 2011). Allergen- and PreS-speciﬁc IgG
as well as IgG1-IgG4 subclass levels were measured by ELISA
(Gallerano et al., 2015). Timothy grass pollen allergen extract-,rPhl p
1-, rPhl p 2-, rPhl p 5-, and rPhl p 6-specﬁc IgE antibody levels (kUA/l)
before and after treatment were quantiﬁed with a Phadia 250
ImmunoCAP system (Thermo Fisher). A comparison of IgE reactivities
to the puriﬁed recombinant grass pollen allergens, to the BM32 deriva-
tives (BM321, BM322, BM325 and BM326) and PreS in pre-treatment
sera was performed by ELISA (Niederberger et al., 2015).
Furthermore, allergen-speciﬁc IgE and IgG binding tomicro-arrayed
allergens was measured using ImmunoCAP ISAC technology (Thermo
Fisher). This technology utilizes low amounts of micro-arrayed aller-
gens and can be used to visualize the competition of allergen-speciﬁc
IgG with allergen-speciﬁc IgE binding by a reduction of IgE binding
(Lupinek et al., 2014, Wollmann et al., 2015).
Allergen-induced basophil activationwas determined in heparin-
ized blood samples obtained before and after treatment by measur-
ing the up-regulation of CD203c expression on basophils upon
exposure to a mix of increasing concentrations of the four major tim-
othy grass pollen allergens (rPhl p 1,2,5,6) containing 1, 5, 25 and
125 pg/ml of each allergen compared to buffer control (phosphate-
buffered saline = PBS)
Mean ﬂuorescence intensities of stimulated (MFIstim) and
unstimulated (MFIcontrol) cells are determined for triplicate cul-
tures by ﬂow cytometry and the up-regulation of CD203c expression
is expressed as stimulation index (MFIstim : MFIcontrol) (SI)
(Hauswirth et al., 2002).
Peripheral blood mononuclear cells (PBMC, 2 × 105/well) prepared
from patients heparinized blood samples before and after treatment
were cultured in triplicates in 96-well plates (Nunclone; Nalge Nunc In-
ternational, Roskilde, Denmark) and stimulated with a mix containing
0.25 μg/well of each of the four major timothy grass pollen allergens al-
lergens, rPhl p 1, 2, 5 and 6) as described (Niederberger et al., 2015). The
levels of in vitro allergen-induced cytokine responses (IL-1b, IL-2, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, INF-γ, TNF-α, C-GSF, GM-
CSF, MCP-1, and MIP-1b) were measured using Bio-Plex ProTM human
cytokine 17-plex immunoassay (Bio-Rad Inc., Hercules, CA) using a
Luminex 100 System (Luminex Corp. Austin, Tx). Allergen-induced T
cell proliferation was determined in triplicate PBMC cultures obtained
after treatment. This was done by measuring the T cell proliferation
upon stimulation with the allergen mix in the presence of serum
(50μl) obtained before or after treatment for each patient by thymidineup-take (Focke-Tejkl et al., 2015). Stimulation indices (SIs) were calcu-
lated as the quotient of the mean cpms obtained for cultures with aller-
gen and medium alone. For patients with SIs higher than 1 the cpm
differences between the allergen-induced proliferation with serum be-
fore and after treatment were calculated. For logistic reasons it was
not possible to obtain and process samples for cellular experiments
from all patients and therefore results are shown only for those patients
where experiments could be performed.
2.6. Statistical analysis
The primary efﬁcacy endpoint (difference in the TNSS2-6h before
and after treatment) was analyzed using a stepwise, hierarchical proce-
dure (Tamhane et al., 1996), which respects the overall α-level of 5%:
The three BM32 dose groups were each compared to placebo using
one-sided t-tests at α= 0.05. Further analyses on the primary efﬁcacy
endpoint were conducted using ANOVAs with ﬁxed factors treatment
and strata moderate and severe allergy. Changes in TNSS2-6h before
and after treatment within each treatment group were analyzed using
a paired t-test.
AUC2-6h of TNSS and TNNSS before and after treatment as well as
the change in AUCs were analyzed with descriptive statistics and
displayed graphically (mean and 95% CI) for each group. Absolute
changes in AUCwithin each treatment group before and after treatment
were looked at using paired t-tests. Comparisons between each verum
and placebo group of absolute AUCs values at each visit and change
from pre-treatment AUCs were done applying the same ANOVA
model like for the primary efﬁcacy parameter. The mean of TOSS
(which is a component of TNNSS and thus a post hoc analysis) was cal-
culated, the change between pre and post treatment was given in % of
baseline value.
Changes in the skin reaction to grass pollen extract, determined by a
titrated skin prick test before and after the treatmentwere evaluated via
measuring wheal areas at screening and at visit 7. In addition, the
change in the threshold concentration of grass pollen extract necessary
to provoke a positive skin reaction was evaluated. Results were ana-
lyzed by descriptive statistics and Fisher´s exact t-test was applied to
evaluate differences between the groups.
Antibody evaluations used a signed-rank Wilcoxon test for evaluat-
ing paired differences before and after treatmentwithin each treatment
group, and the Kruskal-Wallis test to check for a global difference be-
tween treatment groups.
All tests except the ones for the primary efﬁcacy endpointwere done
on an explorative two-sided 5% signiﬁcance level. Details regarding the
statistical analyses of secondary endpoints can be found in the Supple-
mental materials (Study protocol and Statistical analysis plan).
Conﬁrmatory testing of theprimary efﬁcacyparameterwas based on
the full-analysis set (FAS). All secondary endpoints used the FAS aswell.
Further evaluations of the primary efﬁcacy endpoint as well as selective
secondary endpoints used the per-protocol population (PP) as
indicated.
3. Results
3.1. Vaccination with BM32 reduces grass pollen-induced rhinitis and im-
mediate skin responses
A signiﬁcant decrease of the TNSS after treatment was found in pa-
tients of groups S2:20 μg and S3:40 μg with a mean reduction of 1.41
(p = 0.03) and 1.34 (p = 0.003), respectively (Figs. 3 and 4). Mean
changes of TNSS in the placebo and S1:10 μg groupswere not signiﬁcant
(Fig. 4A). Fig. 3 shows no difference regarding the development of the
TNSS in the four treatment groups over the 6 hours pollen exposure in
the challenge chamber at baseline (Fig. 3A). After treatment patients
from groups S2:20 μg and S3:40 μg showed lower TNSS during almost
the entire chamber session (i.e., between hours 1 and 6) when
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Fig. 3.A–D Time course of themean total nasal symptom scores recorded for the four treatment groups in the challenge chamber at baseline and after vaccination. Shown are themeans of
the total nasal symptom scores (y-axes) recorded for the four treatment groups over a period of 360 min (x-axes) before treatment at baseline and after the three injections (post) for all
patients and after removal of subject 47 (A: baseline TNSS; B: TNSS post; C: baseline TNSS-subj 47; D: TNSS-subj 47 post). (S1: 10 μg— red lines; S2: 20μg— green lines; S3: 40 μg— purple
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tients from group S1:10 μg showed higher TNSS than placebo-treated
patients. A post hoc analysis of the placebo-treated patients revealed
that this difference was due to one placebo subject (i.e., subj. 47) who
showed an unusual drop of TNSS of 10 points (i.e., 12 to 2) compared
to the baseline sessionwhichwas not compatiblewith objective param-
eters obtained by active anterior rhinomanometry (data not shown).
The post hoc removal of subject 47 did not affect the TNSS results atA: TNSS: change from baseline – 
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After treatment, a dose-dependent reduction of TOSS was observed
(11% for S1:10μg; 23% for S2:20μg; 24% for S3:40μg) whereas the place-
bo group remained unchanged (Fig. 5).
Quantitative skin prick test titration with grass pollen allergen ex-
tract before and after treatment showed a dose-dependent reduction
of allergen-speciﬁc skin sensitivity after treatment which was mostB: TNSS: change from baseline – 
PP population minus patient 47
4
5
6
7
8
9
10
Placebo S3: 40µg S2: 20µg S1: 10µg
M
ea
n
 T
N
SS
 (2
-6h
)
n=17
treatment
pre- post-
p=0.154
-9% p=0.003
-20%
p=0.030
-24%
p=0.102
-10%
n=16 n=18 n=16
pre- post- pre- post- pre- post-
nsns
***
ent group themean TNSS at baseline (pre-) and after vaccination (post-) is shownwith p-
etricmeans (A: PP population, B: PP populationwithout subject 47). (S1: 10 μg— red bars;
0%
5%
10%
15%
20%
25%
30%
-24%
-11%
-23%
-1%
Fig. 5. TOSS in the treatment groups. Shown is the reduction of TOSS after treatment
compared to baseline in the per protocol population (blue = placebo, purple = 40 μg
dose, green = 20 μg dose, red = 10 μg dose). Percentage changes compared to baseline
are indicated.
49P. Zieglmayer et al. / EBioMedicine 11 (2016) 43–57pronounced in the S2:20 μg and S3:40 μg group when compared to
baseline (Fig. 6A, B). We found a dose-dependent reduction of the
mean wheal areas in the patients of the S2:20 μg and S3:40 μg group
when compared to baseline whereas the placebo and the S1:10 μg
group showed no or a low reduction in wheal reactions (Fig. 6B). The
mean reduction was largest for the S3:40 μg group (−10.96 mm2; SD
24.64) followed by the S2:20 μg group (−7.43mm2; SD 18.89)whereas
therewere only very little changes for the S1:10 μg group (−0.20mm2;
SD 16.41) and placebo group (+0.96 mm2; SD 16.04). (Fig. 6B). Like-
wise, we found a dose-dependent reduction of the sum of wheal areas
of the S2:20 μg (−266.8; SD 257.20) and S3:40 μg (−335.4; SD
371.06) group when compared to baseline and again the S1:10 μg
group (−195.8; SD 225.86) was similar to placebo (−199.6; SD
284.71) (Fig. 6A).
By SPT endpoint titration we found that 5 out of 18 patients from
group S2:20μg and 5 out of 16 patients of group S3: 40μg shifted their
sensitivities at least to 1:8 or 1:4 whereas such a shift was observed
only for 2 out of 16 patients from group S1 and only for one out of 18
of the placebo group (data not shown).
3.2. High doses of BM32 are well-tolerated
All but two subjects concluded the study per protocol. Two subjects,
one from the S1:10 μg and one from the S3:40 μg group, withdrew con-
sent due to restriction in study visit availability (Fig. 2A). Themajority of
TAEs were local injection site late phase reactions. Local injection site-400
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Percentage changes compared to baseline are indicated.reactions occurred in both actively- and placebo-treated patients.
There was no signiﬁcant difference regarding the frequency of occur-
rence of these reactions but a dose-dependent trend to higher inten-
sity of the local reactions in the verum groups (Table 2). No systemic
grade 2, 3 or 4 reactions were observed. All systemic TAEs were late
phase reactions (i.e., occurred after several hours) of grade 1. They
included allergic rhinitis in 7 actively treated patients and 1 conjunc-
tivitis in the S3:40 μg group. Cutaneous reactions were one ﬂush, one
event of itching and palmar erythema and urticarial reactions in
three patients (Table 2). No systemic reactions were observed in
the placebo group.
3.3. Vaccinationwith BM32 induces grass pollen allergen-speciﬁc IgG with-
out boosting allergen-speciﬁc IgE responses
Fig. 7 shows that immunotherapy with each of the three doses of
BM32 but not with placebo induced highly signiﬁcant (p b 0.0001) in-
creases of IgG antibodies speciﬁc for the four major grass pollen aller-
gens as well as to the PreS carrier protein which inﬂuenced also
cellular responses. The induced allergen-speciﬁc IgG antibodies are spe-
ciﬁc for the peptides included in BM32 but recognize also the peptides
in the context of the complete allergens (data not shown; Focke-Tejkl
et al., 2015). The BM32-induced IgG response was mainly composed
of allergen- and PreS-speciﬁc IgG1 and IgG4 responses as well as some
IgG2 responses whereas the IgG3 response was negligible (Fig. 8A-E).
Signiﬁcant BM32-induced allergen-speciﬁc IgG responses were also de-
tected usingmicro-arrayed allergenmolecules (Fig. 9). Immunotherapy
with BM32 did not lead to any relevant increases of allergen-speciﬁc IgE
levels (Fig. 7B). Only for the low doses (i.e., S1 and S2) a slight induction
of Phl p 6-speciﬁc IgE was noted whereas no signiﬁcant increases were
found for the three doses for Phl p 1, Phl p 2, Phl p 5 and for the high
dose (i.e., S3) for Phl p 6 (Fig. 7B). The quantiﬁcation of timothy grass
pollen allergen-speciﬁc IgE levels showed that there were no signiﬁcant
increases after treatments with BM32 (Fig. 10). When we assessed
allergen-speciﬁc IgE reactivity to micro-arrayed allergens by chip test-
ing, an assay where low amounts of allergens are immobilized to the
solid phase, we found signiﬁcant reductions of allergen-speciﬁc IgE
binding for Phl p 1 and Phl p 2 when comparing the three BM32 doses
with placebo and signiﬁcant reductions of IgE binding for Phl p 5 (S3
versus placebo) and Phl p 6 (S2 and S3 versus placebo) (Fig. 11).
3.4. IgG antibodies induced by vaccination with BM32 inhibit allergen-
induced basophil degranulation and T cell proliferation
We found a signiﬁcant reduction of allergen-induced up-regulation
of CD203c expression for the BM32-treated patients in the increasing
part of the curve of the dose-dependent basophil activation whereas-12
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Table 2
Summary of treatment-associated adverse events.
Organ speciﬁc reaction
BM32/S1
(N = 17)
BM32/S2
(N = 18)
BM32/S3
(N = 17)
Placebo
(N = 18)
Total
(N = 70)
Number of subjects (%) event count
Injection site reaction 17 (100.0) 47 17 (94.4) 57 17 (100.0) 51 17 (94.4) 48 68 ( 97.1) 203
Allergic rhinitis 3 (17.6) 4 0 (0.0) 0 4 (23.5) 5 0 (0.0) 0 7 (10.0) 9
Cutaneous reactions 1 (5.9) 2 2 (11.1) 3 1 (5.9) 1 0 (0.0) 0 4 (5.7) 6
Allergic conjunctivitis 0 (0.0) 0 0 (0.0) 0 1 (5.9) 1 0 (0.0) 0 1 (1.4) 1
Flushing 1 (5.9) 1 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0 1 (1.4) 1
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Fig. 7.Grass pollen allergen-speciﬁc immunological changes in the treatment groups before and after vaccination. (A) IgG levels speciﬁc for Phl p 1, Phl p 2, Phl p 5, Phl p 6 and PreS (y-axes:
OD levels, horizontal bars denote medians) in sera from the four patient groups (S1: 10 μg; S2: 20 μg; S3: 40 μg; placebo) before (pre) and after (post) treatment. (B) IgE levels speciﬁc for
Phl p 1, Phl p 2, Phl p 5 and Phl p 6 (y-axes: OD levels, horizontal bars denotemedians) in sera from the four patient groups (S1: 10 μg; S2: 20 μg; S3: 40 μg; placebo) before (pre) and after
(post) treatment. Signiﬁcant differences between pre and post samples are indicated (****p b 0.0001; ***p b 0.001; **p b 0.01; *p b 0.05). (C) Grass pollen allergen-induced up-regulation of
CD203c expression (y-axes: SIs as box plots with indicatedmedians, whiskers=minimumandmaximum; boxes= 25th to 75th percentiles) in tested blood samples from patients of the
active treatment groups (S1: 10 μg, n = 4; S2: 20 μg, n = 4; S3: 40 μg, n = 2) or the placebo group (n = 6) for different allergen concentrations (x-axes) before (pre) and after (post)
treatment. Signiﬁcant differences between pre and post samples are indicated (**p b 0.01; *p b 0.05). (D) Reduction of allergen-induced T cell proliferation in PBMCs (y-axes: counts
per minute, cpm reductions as box plots with indicated medians, whiskers = minimum and maximum; boxes = 25th to 75th percentiles) after pre-incubation of allergens with post-
treatment sera versus pre-incubation with pre-treatment sera for placebo (n = 6) and actively treated patients (n = 19) and for the individual treatment groups (S1: 10 μg, n = 6;
S2: 20 μg, n = 7; S3: 40 μg, n = 6; placebo, n = 6). Signiﬁcant differences in the cpm reductions between actively and placebo treated patients are indicated.
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52 P. Zieglmayer et al. / EBioMedicine 11 (2016) 43–57no reduction of basophil activation was observed for placebo-treated
patients after treatment (Fig. 7C).
Next we assessed whether BM32-induced allergen-speciﬁc IgG
antibodies inﬂuence allergen-induced T cell proliferation (Fig. 7D).
Pre-incubation of allergens with post-treatment sera containingtreatment-induced allergen-speciﬁc IgG antibodies obtained from
BM32-treated patients inhibited PBMC proliferation more than pre-
incubation with post-treatment sera from placebo-treated patients
without treatment-induced allergen-speciﬁc IgG antibodies for
each of the three BM32 doses (Fig. 7D). This effect (i.e., reduction
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Fig. 9.Allergen-speciﬁc IgG responses tomicro-arrayed grass pollen allergens. Shown are IgG levels (y-axes: ISU; horizontal bars denotemedians) for Phl p 1, Phl p 2, Phl p 5, Phl p 6 in sera
from the four patient groups (S1: 10 μg; S2: 20 μg; S3: 40 μg; placebo) before (pre) and after (post) treatment. Signiﬁcant differences between pre and post samples are indicated
(****p b 0.0001; ***p b 0.001; **p b 0.01; *p b 0.05).
53P. Zieglmayer et al. / EBioMedicine 11 (2016) 43–57of T cell proliferation as measured by counts per minute reduction)
was statistically signiﬁcant when the results from the three BM32
doses were compared to placebo (p = 0.0063). Fig. 12 shows the
levels of allergen-induced cytokines (IL-5, IL-12, IL-13, IL-10, IL-17
and interferon-gamma) detected before and after treatment in pa-
tients PBMC culture supernatants. We noted a signiﬁcant (p b 0.05)
induction of IL-10 for the lower doses S1 and S2 whereas for S3 a sig-
niﬁcant decrease (p b 0.05) of IL-10 productionwhichwas associated
with signiﬁcant increases of IL-5 and IL-13 (p b 0.05) and a signiﬁ-
cant decrease of interferon gamma (p b 0.05) was noted. The analysis
of the secretion of additional 11 cytokines (see methods) in PBMC
cultures obtained before and after treatment showed no signiﬁcant
changes (data not shown).nsns
ns
ns
kU
A/
l
Fig. 10. Quantiﬁcation of grass pollen allergen-speciﬁc IgE levels in the treatment groups
before and after vaccination. Timothy grass pollen allergen extract-speciﬁc IgE levels
determined by ImmunoCAP (y-axes: kUA/l, horizontal bars denote medians) in sera
from the four patient groups (S1: 10 μg; S2: 20 μg; S3: 40 μg; placebo) before (pre) and
after (post) treatment.4. Discussion
This AIT study is the ﬁrst to investigate safety as well as clinical and
immunological effects of a new strategy for AIT which is based on a B
cell epitope-based recombinant allergy vaccine. It shows that three
monthly injections of a vaccine consisting of four recombinant fusion
proteins combining non-allergenic peptides derived from the four
major timothy grass pollen allergens, Phl p 1, 2, 5 and 6 with the hepa-
titis B preS protein are effective in reducing allergen-induced immediate
allergic reactions as demonstrated by the reduction of TNSS, TOSS and
immediate skin responses in grass pollen allergic patients. We consider
the reduction of the TNSS observed after vaccinationwith the 20 and 40
μg dose of BM32 as relevant because itsmagnitude is comparable to that
observed after administration of systemic antihistamines in the pollen
chamber model (Horak et al., 2010). Furthermore, it has been demon-
strated that a one point difference in the rhinoconjunctivitis total symp-
tom score is clinically relevant in grass pollen-induced allergic
rhinoconjunctivitis (Devillier et al., 2014).
The study further shows that the new B cell epitope based vaccine
was very well tolerated although high doses of up to 160 μg of the
four recombinant proteins per injection were administered without
any up-dosing. In fact, the previous in vitro assessment of BM32 had
shown that the vaccine exhibited almost no IgE reactivity and allergenic
activity when exposed to basophils of allergic patients (Focke-Tejkl
et al., 2015). It was found that allergic patients failed to exhibit any rel-
evant immediate type skin reactions even when tested at the height of
the grass pollen season (Niederberger et al., 2015).We also had reduced
the presence of grass allergen-speciﬁc T cell epitopes in BM32 but a
complete elimination of all T cell epitopes is not possible due to the di-
versity of allergic patients T cell epitope recognition.However, we found
that the reduction of allergen-speciﬁc T cell epitopes in the vaccine re-
sulted in a strong reduction of T cell and pro-inﬂammatory cytokine re-
sponses when BM32 was tested in PBMC cultures from grass pollen
allergic patients (Focke-Tejkl et al., 2015). Accordingly, no late skin re-
sponses were found in grass pollen allergic patients when BM32 was
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Fig. 11. Changes of IgE-binding to micro-arrayed allergens in the treatment groups. Shown are the percentages reduction of IgE binding (box plot representations of the 25th to 75th
percentiles, horizontal bars denote medians, whiskers = minimum and maximum) to Phl p 1, Phl p 2, Phl p 5 and Phl p 6 in the four patient groups (S1: 10 μg; S2: 20 μg; S3: 40 μg;
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Fig. 12. Changes of allergen-induced cytokine secretion in cultured PBMC obtained from the patients before and after treatment. Shown are the levels of cytokines (IL-5, IL-12, IL-13, IL-10,
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54 P. Zieglmayer et al. / EBioMedicine 11 (2016) 43–57
55P. Zieglmayer et al. / EBioMedicine 11 (2016) 43–57applied by atopy patch testing (Niederberger et al., 2015).The latter
study indeed suggests that BM32 has a strongly reduced potential to in-
duce late phase, T cell-mediated side effects in patients.
Here, we treated 52 patients with doses of 40–160 μg of the four
recombinant proteins and thus administered 155 injections. Given
that very high doses were injected, the vaccine was very well toler-
ated because very few (i.e., 9 events of late phase rhinitis, 6 events
of late phase cutaneous reactions, 1 late phase conjunctivitis and
one late phase ﬂushing) and mild (i.e., grade 1) late phase systemic
reactions were observed. In contrast, previous “hypoallergenic vac-
cines”which included allergen-speciﬁc T cell epitopes frequently in-
duced late phase reactions (Niederberger et al., 2004, Purohit et al.,
2008, Spertini et al., 2014).The analyses of recombinant hypoaller-
genic T cell epitope-containing derivatives of the major birch pollen
allergen, Bet v 1 (Purohit et al., 2008) by atopy patch testing indicat-
ed that these reactions most likely originated from T cell activation
(Campana et al., 2015). Likewise, it was found that a T cell epitope-
containing vaccine for birch pollen allergy (AllerT) based on peptides
of the major birch pollen allergen Bet v 1 frequently caused late
phase reactions (Spertini et al., 2014). During the administration of
75 injections of T cell epitope-containing peptides of Bet v 1, 31
events of late phase dyspnoe and 36 late phase cutaneous reactions
were observed with AllerT (Spertini et al., 2014). We therefore
think that the reduction of allergen-speciﬁc T cell epitopes in BM32
and their replacement by the allergen-unrelated carrier protein
PreS has contributed to the tolerability of BM32. We have already
constructed several hypoallergenic derivatives for allergens fromdiffer-
ent allergen sources (e.g., cat, birch, house dustmites) using PreS as car-
rier protein (Niespodziana et al., 2011, Marth 2012, Banerjee et al.,
2014).The in vitro and experimental animal data collected for all these
derivatives suggest a similar mode of action of these vaccines. Upon in-
jection they induce allergen-speciﬁc IgG responses towards the IgE
binding sites of the corresponding allergens with T cell help derived
from the PreS carrier protein. In fact our study demonstrates for the
ﬁrst time in humans that BM32 induces strong allergen-speciﬁc IgG re-
sponses which appear to suppress immediate type allergic reactions as
shown by the reduction of TNSS upon pollen exposure and by the re-
duction of immediate type skin responses. The reduction of allergen-
induced basophil responses after treatment indeed suggests that the
treatment induced IgG antibodies which prevent the allergens from
interacting with IgE on the surface of mast cells and basophils and
that this may be the major underlying mechanism. This was also mir-
rored by results from an in vitro assay inwhichwemeasured the reduc-
tion of IgE binding by therapy-induced IgG in an IgE binding assay in
which we can visualize the IgE-blocking effect of IgG using small
amounts of solid phase bound allergens using allergen micro-arrays
(Fig. 11). AIT with BM32 such as subcutaneous AIT with natural aller-
gens reduces IgE binding to micro-arrayed allergens through induction
of IgG competing with IgE for allergen binding (Wollmann et al., 2015,
Schmid et al., 2016, Lupinek et al., 2016). The analysis of the allergen-
speciﬁc isotype and subclass responses showed that BM32 mainly in-
duced allergen-speciﬁc IgG responses (IgG1=IgG4 N IgG2) which is sim-
ilar to allergen-extract based vaccines which are in clinical use and are
formulated with Aluminum hydroxide (Gadermaier et al., 2010;
Gadermaier et al., 2011) or with Th1-driving adjuvants such as
monophosphoryl lipid-A (Mothes et al., 2003).
We furthermore observed previously that allergen-speciﬁc IgG re-
sponses induced by PreS-based vaccines can inhibit IgE-facilitated aller-
gen presentation to T cells in in vitro studies (Marth et al., 2013). In this
study we were able to demonstrate that this mechanism, which was
earlier described for AIT with natural allergens (van Neerven et al.,
1999),may be also operative in BM32-treated patients. In fact, the addi-
tion of post-treatment sera containing therapy-induced allergen-
speciﬁc IgG to allergens signiﬁcantly suppressed allergen-induced T
cell proliferation suggesting that one can obtain “T cell tolerance”with
a B cell epitope-based vaccine.Another potential advantage is that BM32 induced selectively
allergen-speciﬁc IgG responses but did not induce boosts of allergen-
speciﬁc IgE production. In fact, allergen extract-based but also
peptide-based vaccines have been shown to induce strong boosts of
allergen-speciﬁc IgE production. For example, sublingual treatment
with grass pollen extract induced a ﬁve-fold increase of allergen-
speciﬁc IgE production (Durham et al., 2006) and a 3-fold increase of
allergen-speciﬁc IgE was found upon AIT with hypoallergenic Bet v 1-
peptides (Spertini et al., 2014). While this may not be a problem for
therapeutic vaccination when much larger amounts of allergen-
speciﬁc IgG are induced at the same time, itmay be a prohibitive feature
if one considers to use a vaccine strategy for prophylactic intervention in
only sensitized but not yet symptomatic children or perhaps even for
the prevention of sensitization (Valenta et al., 2012). It is therefore
quite possible that BM32 and B cell epitope-based vaccines constructed
according to a similar principlemay be especially suitable for prophylac-
tic intervention because our data suggest that they have low IgE sensiti-
zation capacity. In fact data from experimental animal models indeed
indicate that preventive vaccination with carrier-bound B cell epitope
peptides can prevent allergic sensitization (Linhart et al., 2014). A gen-
eral limitation in the ﬁeld of AIT is that different forms of AIT (e.g., SCIT,
SLIT) have not been compared in controlled clinical studies and this also
applies for the present study conducted with BM32.
We also found that BM32 induced PreS-speciﬁc IgG antibodies
(Figs. 7A, 8E). The mapping of the PreS-speciﬁc antibody responses
using synthetic PreS-derived overlapping peptides revealed that the
BM32 induced IgG antibodies reacted with peptides important for the
infection of hepatocytes by hepatitis B virus and also suppressed
in vitro the infection of hepatocytes by hepatitis B (Cornelius et al.,
2016). When we analyzed sera from the present study and another
AIT study conducted in grass pollen allergic patients during two years
of natural grass pollen exposure (ClinicalTrials.gov number,
NCT01538979) we found no difference regarding persons who have re-
ceived previous HBV vaccination and persons who had not been HBV
vaccinated regarding the development of HBV-speciﬁc antibody re-
sponses or adverse events. This ﬁnding together with data from hepati-
tis B vaccination studies conducted with PreS-containing vaccines
(Rendi-Wagner et al., 2006) would even indicate that BM32 may not
only protect against grass pollen allergy, but eventually also against
hepatitis B infections which would offer an additional advantage
(Gerlich and Glebe, 2016). Persons with HBV-infections have not yet
been treated with BM32 but it is planned to study if BM32 or one of
its components can be used for therapeutic and eventually prophylactic
vaccination against HBV infections.
Taken together our results encourage to further evaluate BM32 in
larger clinical studies for its efﬁcacy for treating grass pollen allergic pa-
tients. Data froma phase IIb study inwhichmore than 150 patients have
been treatedwith BM32 for two years indeed indicate that BM32 is clin-
ically effective for the treatment of grass pollen allergy induced by nat-
ural grass pollen exposure (ClinicalTrials.gov number, NCT01538979).
The present study provides evidence for clinical efﬁcacy after a short
course of treatment in a pollen chamber setting. A limitation of our
study is that we do not have data if prolonged treatment with BM32
has long-termbeneﬁcial effects on grass pollen allergy. Therefore, future
studies are necessary to investigate if vaccination with BM32 has such
long-term and disease-modifying effects. Furthermore, work is in prog-
ress to move B cell epitope-based vaccines for house dust mite, cat and
birch pollen allergy based on the PreS-fusion protein into clinical
evaluation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.08.022.
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